| Entry |
|
|---|
| Name |
Valproate sodium (USAN);
Sodium valproate (JP17);
Depakene (TN);
Selenica (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C8H15O2. Na
|
|---|
| Exact mass |
166.097
|
|---|
| Mol weight |
166.1933
|
|---|
| Structure |
     |
|---|
| Simcomp |
 |
|---|
| Class |
Neuropsychiatric agent
DG02035 Fatty acid antiepileptics
Other
DG01575 Calcium channel blocker
DG01573 Calcium channel T type blocker
Cyp substrate
DG01633 CYP3A substrate
|
|---|
| Remark |
Therapeutic category: ATC code: Chemical group: |
|---|
| Activity |
Anticonvulsant, Antimanic, Antimigraine, Antiepileptic |
|---|
| Comment |
Fatty acid derivative
|
|---|
| Target |
|
|---|
| Pathway |
| Alanine, aspartate and glutamate metabolism | | Valine, leucine and isoleucine degradation | | beta-Alanine metabolism | | Propanoate metabolism | | Butanoate metabolism | | MAPK signaling pathway | | Calcium signaling pathway | | GABAergic synapse |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| Anticonvulsants | | Calcium channel blocking drugs | | Antimigraines |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AG Fatty acid derivatives
N03AG01 Valproic acid
D00710 Valproate sodium (USAN)
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
Valproate
D00710 Valproate sodium (USAN)
Antimigraine Agents
Prophylactic
Valproate
D00710 Valproate sodium (USAN)
Bipolar Agents
Mood Stabilizers
Valproate
D00710 Valproate sodium (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D00710 Valproate sodium (USAN); Sodium valproate (JP17)
117 Psychotropics
1179 Others
D00710 Valproate sodium (USAN); Sodium valproate (JP17)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated cation channels
Ca2+ channel, CACN alpha-1, CaVx.x
calcium channel T type
Valproic acid
D00710 Valproate sodium (USAN)
Enzymes
Transferases
histone acetyltransferase
Valproic acid
D00710 Valproate sodium (USAN)
GABA transaminase
Valproic acid
D00710 Valproate sodium (USAN)
Hydrolases
histone deacetylase
Valproic acid
D00710 Valproate sodium (USAN)
Cytochrome P450 interactions [BR:br08309]
CYP substrates
CYP2C9
Valproic acid
D00710 Valproate sodium (USAN)
CYP3A4
Valproic acid
D00710 Valproate sodium (USAN)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00710 Sodium valproate
D00710 Sodium valproate tablets
D00710 Sodium valproate syrup
Neurological agents [br08367.html]
Antiepileptic agents
D00710
Anesthetics, analgesics and anti-inflammatory drugs [br08369.html]
Therapeutic / prophylactic agents for migraine
D00710
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
Polymorphisms and germline mutations
D00710
 |
|---|
| Other DBs |
CAS: 1069-66-5 PubChem: ChEBI: ChEMBL: LigandBox: NIKKAJI: |
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 11
1 C1c C 24.8619 -18.6957
2 C1b C 24.8619 -17.3175
3 C1b C 23.6530 -19.4139
4 C6a C 26.0650 -19.4139
5 C1b C 23.6472 -16.6109
6 C1b C 22.4441 -18.6957
7 O6a O 27.2738 -18.6957
8 O6a O 26.0650 -20.8098 #-
9 C1a C 22.4384 -17.3175
10 C1a C 21.2412 -19.4139
11 Z Na 28.5001 -20.7280 #+
BOND 9
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 3 6 1
6 4 7 2
7 4 8 1
8 5 9 1
9 6 10 1
|
|---|
